TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05807945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.75%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution
Description: The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
Study: NCT01666366

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Study: NCT00260338

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: stem cell
Description: mesenchymal stromal cell
Study: NCT04270019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: In order to prepare PEG 3350 50% weight/volume, 25 grams of the sterilized PEG 3350 will be measured out and placed into a sterilized glass bottle then 25 mL of sterile water will be added. The solution will be allowed to rest for 10 minutes so that dissolution may occur. More sterile water will then be added so the total volume is 50mL. This solution will then be sterilized by the Halifax Health Infirmary pharmacy department using a liquid autoclave cycle of 120 degrees Celsius for 20 minutes in a glass vial. The 50 mL solution will be portioned into 2mL sterilized glass vials using a standard aseptic technique. The solutions will be kept at a solid frozen state between negative 25 degrees Celsius and negative 10 degrees Celsius for a maximum of 45 days. The solutions will be removed from storage on the day of surgical utilization in order to ensure storage guidelines are kept to the highest standards.
Study: NCT02557217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP202
Description: Active
Study: NCT01334892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Inhalation Solution
Description: Cyclosporin for inhalation twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclosporine Inhalation Solution
Description: Cyclosporin for inhalation twice daily
Study: NCT00775216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus telephone helpline
Description: A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
Study: NCT01863953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-Combination Bimatoprost/Brimonidine
Description: One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
Study: NCT02557217

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00128817

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiation
Description: 60-70 Gy at 2Gy/5days a week for 6 to 7 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngectomy + adjuvant radiotherapy/chemoradiotherapy
Description: Surgery: Total Laryngectomy with or without partial pharyngectomy or Near-Total Laryngectomy with or wothout partial pharyngectomy Adjuvant Radiation 2- 3 weeks following surgery: 50-60Gy at 2Gy/5days a week for 5 to 6 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
Study: NCT01784237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior meatoscopy
Description: The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal sniff test
Description: All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
Study: NCT01863953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost Ophthalmic Solution 0.01%
Description: One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate Ophthalmic Solution 0.2%
Description: One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
Study: NCT00634400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00960739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan hydrochloride
Description: The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iobenguane I 131
Description: 444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)
Study: NCT00400231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study drugs: Metformin and fenofibrate
Description: 145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study Drug: Metformin
Description: 2000mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study Drug: fenofibrate
Description: 145mg/day of fenofibrate
Study: NCT02091310

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505
Study: NCT00400231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin and Fenofibrate placebo
Description: placebo metformin and fenofibrate
Study: NCT04095832

Intervention type: PROCEDURE
Intervention: Epidural anesthesia
Description: Epidural anesthesia using standardized technique

Intervention type: PROCEDURE
Intervention: Epidural anesthesia
Description: Epidural anesthesia using standardized technique
Study: NCT03851471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jiu-wei-zhen-xiao Granule
Description: Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
Study: NCT01104701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide once weekly
Description: subcutaneous injection, 2 mg, once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once monthly suspension
Description: subcutaneous injection, low dose, once a month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once monthly suspension
Description: subcutaneous injection, medium dose, once a month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once monthly suspension
Description: subcutaneous injection, high dose, once a month
Study: NCT04773119

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI only
Description: Patients in this group receive PVI only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI with substrate ablation
Description: Patients in this group receive PVI as well as substrate ablation
Study: NCT04625816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body tilt device (Spine Balance 3D)
Description: The symmetry of the deep muscle was evaluated using a whole body tilt device (Spine Balance 3D, Cyber Medic Co., Ltd., Korea). Spine Balance 3D can evaluate the maintenance strength and maximum strength of the core muscles, and perform a personalized core muscle training program based on the evaluated results.
Study: NCT00437892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: tablets, 40 mg day, 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: tablets, 40 mg once daily
Study: NCT02091310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Study: NCT04448041

Intervention type: OTHER
Intervention: Malnutrition screening
Description: Primary comparison: Prevalence of malnutrition and impact on 30-day outcomes in patients undergoing surgery for cancer
Study: NCT00437892

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: daily diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: daily diet
Study: NCT01683019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeoSync EEG Synchronization Therapy
Description: Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeoSync EEG Synchronization Therapy
Description: Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NeoSync EEG Synchronization Therapy
Description: A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
Study: NCT02846818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
Study: NCT02013232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study: NCT02212886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA Depot 80 mg
Description: Recruitment completed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA Depot 40 mg
Description: Recruitment completed
Study: NCT00562393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional
Description: Overfeeding high fat diet for 28 days
Study: NCT03983161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Fedratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Fedratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Fedratinib
Study: NCT00849537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Injection of intravitreal Triamcinolone
Study: NCT03983161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Fedratinib
Study: NCT04582175

Intervention type: PROCEDURE
Intervention: angioplasty
Description: angioplasty of all non-culprit lesions
Study: NCT03906136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab/Adalimumab-Biosimilar
Description: Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab-Biosimilar, s.c.
Study: NCT02527889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 8-week resistive exercise training
Study: NCT02312440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.~60 Milliliters（ml） by irrigation for 3 minutes before wound closure.
Study: NCT04171661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SASS
Description: SASS applied on chronic skin wounds as skin graft
Study: NCT03829280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training
Description: Psychosocial treatment using environmental supports to bypass cognitive and motivational problems and improve adaptive behavior

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Treatment
Description: Medication follow-up and case management as provided in usual community care in the setting
Study: NCT02723357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching
Description: Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
Study: NCT03906136

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care
Description: Patients will receive treatment according to local practice standards by their treating physician following the current treatment recommendations.
Study: NCT02504996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 g paracetamol via intravenous route in 100 ml normal saline
Study: NCT02723357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to Social Service Referrals
Description: Access to referrals for common social needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to Social Service Referrals
Description: Access to referrals for common social needs.
Study: NCT01853358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cell infusion
Description: * level 1: 1 x 10e6 NK cells /kg;~* level 2: 5 x 10e6 NK cells /kg;~* level 3: \> 5.10e6 and ≤ 5.10e7 cellules NK/kg
Study: NCT02433509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hUCB
Description: 1. The cord blood need to be infusion within less than 10 days after the onset of stroke, and the cord blood mononuclear cells 200 million \~ 500 million will used.~2. 20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion .
Study: NCT01944982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Expanded haploidentical natural killer cells (NKAEs)
Study: NCT04296240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and capecitabine
Description: Patients receive 5-Fu and oxaliplatin based neoadjuvant chemotherapy for 3 months
Study: NCT02504996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: 0.1 mg/kg morphine via intravenous route in 100 ml normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous 100 ml normal saline
Study: NCT05342610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distant reiki
Description: Reiki; It is the transfer of energy to other people by the hands of the person who receives the theoretical training and attunement (initiation) from the reiki master, close or distant. When the hands are brought closer to the body in suitable positions or when the reiki practitioner visualizes the person in his/her thoughts, the energy flow starts spontaneously and the transferred energy is shaped according to the needs of the reiki recipient. The biggest advantage of Reiki; It is an easy and cost-effective method to ensure that the individual restores the balance between body, mind and spirit, has no side effects, has no negative effects on behavior and attitudes.
Study: NCT04296240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision
Description: Patient receive total mesorectal excision after neoadjuvant chemotherapy
Study: NCT02760862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone 100mg.
Description: Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol 20% intravenous fluid
Description: group (II), received mannitol 20% 100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis. Urinary catheter was inserted for patients in group (II) under complete aseptic conditions by the anesthesia resident before the start of mannitol infusion and removed after its discontinuation, accompanied by the intravenous fluid infusion over 48 hours of 500ml of normal saline or Ringer's solution every 8 hours and the input/output fluid chart for evaluation of fluid balance.
Study: NCT00282438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cells will be injected after conditioning

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: Allogeneic stem cells will be injected after conditioning
Study: NCT01015053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral ultrasound-guided rectus sheath block
Description: Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
Study: NCT01464892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting and Reprocessing Therapy
Description: This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STAIR + Imagery Rescripting
Description: A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.
Study: NCT01187433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus
Description: 0.5 mL, Subcutaneous (SC)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Meningococcal A+C vaccine
Description: 0.5 mL, Intramuscular
Study: NCT02528175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided focused ultrasound
Description: Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Radiation
Description: 30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 3.5 weeks concurrent with radiation therapy (institutional standard).